Published by the NCC group in Korea, this study reported outcomes of 45 patients including 37 had recurrent and/or residual disease treated with PBT to a total dose of 70 Gy equivalent in 10 fractions. No grade ≥3 acute toxicity occurred. The median follow-up duration was 35.1 months, local progression occurred in two patients (8.7%).
The 3-year rates of LPFS and overall survival (OS) were 95.2% and 86.4%. The study concluded that hypofractionated PBT showed promising LPFS and OS.